Pacific Biosciences of California, Inc.
PACB
$1.32
$0.043.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 39.01M | 37.18M | 44.65M | 38.44M | 39.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.01M | 37.18M | 44.65M | 38.44M | 39.77M |
| Cost of Revenue | 26.19M | 23.65M | 40.29M | 22.28M | 24.88M |
| Gross Profit | 12.82M | 13.52M | 4.36M | 16.16M | 14.89M |
| SG&A Expenses | 33.39M | 31.15M | 35.75M | 31.10M | 36.18M |
| Depreciation & Amortization | 1.02M | 1.02M | 1.02M | 1.02M | 1.02M |
| Other Operating Expenses | -- | -- | 4.18M | -- | 24.00K |
| Total Operating Expenses | 83.62M | 75.43M | 104.71M | 77.24M | 84.62M |
| Operating Income | -44.61M | -38.25M | -60.06M | -38.80M | -44.85M |
| Income Before Tax | -44.68M | -8.09M | -40.17M | -37.62M | -41.90M |
| Income Tax Expenses | 58.00K | 184.00K | 202.00K | 383.00K | 35.00K |
| Earnings from Continuing Operations | -44.74M | -8.28M | -40.37M | -38.00M | -41.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.74M | -8.28M | -40.37M | -38.00M | -41.93M |
| EBIT | -44.61M | -38.25M | -60.06M | -38.80M | -44.85M |
| EBITDA | -40.75M | -35.03M | -56.31M | -35.32M | -41.18M |
| EPS Basic | -0.14 | -0.03 | -0.13 | -0.13 | -0.14 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.11 | -0.08 | -0.09 |
| EPS Diluted | -0.14 | -0.03 | -0.13 | -0.13 | -0.14 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.11 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 310.66M | 305.82M | 301.91M | 300.84M | 300.16M |
| Average Diluted Shares Outstanding | 310.66M | 305.82M | 301.91M | 300.84M | 300.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |